Ambea AB ( publ ) Stock: price and insider trades · Sweden

Every trade that managers of Ambea AB ( publ ) disclose to Finansinspektionen is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Solna, Sweden. It was founded in 1996. Over the twelve months to 18 October 2026, 83 filings were filed, from 21 insiders.

Both sides are active: 22 purchases worth €524k and 8 sales worth €101.7M, from 14 insiders and 5 insiders respectively. The net balance comes to €101.2M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. At €99.3M, the sale published on 19 May 2026 by Mark Jensen is the largest of the period (9.5% of market cap). On the buying side, the filings list 6 board members, 3 chief executives and 2 finance chiefs among the declarants.

For context, the typical company on the same exchange (median of 890 companies) published 7 filings over the same period, against 83 filings here. Looking back to 2021, when coverage begins, insiders filed 34 purchases and 10 sales.

In the case of 20 purchases, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase dates back some time: it was published 32 days ago, on 15 September 2026. Filings reach the Finansinspektionen feed a median of 1 day after the trade. The regulation allows three business days to notify a trade (MAR article 19).

Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.